Pharma Expanse (PE) is a business development company focused in two areas: CDMO Services and Pharma Pipeline Assets.Pharma Expanse (PE) is partnered with CDMOs across the supply chain to provide development and manufacturing services for Pharmaceutical and Biotechnology companies. PE currently serves as Business Development for 3 CDMOs, totaling 15 Manufacturing Sites in 7 Countries. Capabilities encompass Small Molecule Drug Substance (including HPAPI), Oral Solid Dosage (Tablets/Capsules), Sterile Drug Product, Regulatory Starting Materials (RSMs), Medicinal Chemistry, and niche manufacturing technologies. It’s an innovative business model – very different than the broker/agent model. For Pharma pipeline assets, Pharma Expanse is also working with a clinical stage anti-infective and women’s health company that is developing first-in-class therapeutics with novel mechanisms of action to treat multidrug resistant pathogens. The lead compound began Phase 1 clinical trials in March 2024. The drug has already received FDA Fast Track and QIDP designations.

Resilience is a manufacturing company specializing in Cell & Gene Therapy, Vaccines, Biologics and Nucleic Acids.

• Joined Fareva as the first Business Development hire located in the US. Tasked with growing North America business from scratch, building brand name and awareness, acquiring RFPs, and winning new business for CMO• Responsible for creating and implementing the sales strategy for North America; ultimately responsible for all Drug Substance accounts/business in the US and Canada

Business Development, Marketing, Advertising, Communications, Market and Competitive Analysis, Key Account Managment at PharmaZell. I also served as the agent to the FDA for PharmaZell's sites in Germany, India and Denmark.

Marketing, Business Development, Competitive Analysis, Financial Analysis, Market Research, and Communications responsibilities at SCYNEXIS.

Provided market analysis to start- up companies and the Office of Technology Licensing at University of Florida.

University of Florida Gene Therapy Center - Vector CoreThe primary role of the Vector Core Laboratory is to provide the service of generating gene therapy vectors. The Vector Core services 5 NIH program project grants worth over $25M and produces over 400 preps per year. The Vector Core is responsible for developing new vector technology in collaboration with Center faculty. Additionally, the vector core continues to refine AAV purification methodologies.